Table 4 Univariate and multivariate Cox regression analyses of SLC2A3 expression and the clinicopathological factors in the discovery set (TCGA COADREAD cohort)
From: Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma: analysis of TCGA data
Overall survival | Disease-free survival | |||
|---|---|---|---|---|
HR(95% CI of HR) | P valuea | HR(95% CI of HR) | P valuea | |
SLC2A3 low | 1.00 (Reference) | 1.00 (Reference) | ||
UVA SLC2A3 high | 1.93 (1.21–3.07) | 0.005 | 2.20 (1.32–3.68) | 0.003 |
MVA SLC2A3 high | 1.98 (1.24–3.17) | 0.004 | 1.85 (1.10–3.12) | 0.020 |
Age < = 65 | 1.00 (Reference) | |||
Age > 65 | 2.61 (1.59–4.28) | < 0.001 | ||
AJCC stage I, II | 1.00 (Reference) | 1.00 (Reference) | ||
AJCC stage III, IV | 3.17 (1.96–5.11) | < 0.001 | 2.48 (1.58–3.89) | < 0.001 |